News & Events: I-SPY 2 Trial

UCSF News reports on new results showing the promise and potential of I-SPY 2 Trial, personalized medicine study designed to identify breast cancer patients most likely to benefit from an array experimental drugs. In an innovative clinical trial led by UC San Francisco, the experimental drug neratinib along with standard chemotherapy was found to be a beneficial treatment for some women with newly diagnosed, high-risk breast cancer. Additionally, researchers learned that an algorithm used in the adaptive, randomized trial known as I-SPY 2 was highly effective at predicting the success of [...]